MD Anderson Cancer Center partnered with IBM Watson to create an advisory tool for oncologists. The tool used natural-language processing (NLP) to summarize patients’ electronic health records, then searched databases to provide treatment recommendations. Physicians tried out a prototype in the leukemia department, but MD Anderson canceled the project in 2016—after spending US $62 million on it.
Outside of corporate headquarters, however, IBM has discovered that its powerful technology is no match for the messy reality of today’s health care system. And in trying to apply Watson to cancer treatment, one of medicine’s biggest challenges, IBM encountered a fundamental mismatch between the way machines learn and the way doctors work
The market — defined as A.I.-related hardware, software and services — will surge from $8 billion this year to $47 billion by 2020, predicts IDC, a research firm.
Also, some coverage of Watson business models, including customized cocktail drugs, which I hear is a scary big business in the horizon.
And, there’s some IBM AI spreadsheeting you can fiddle around with:
IBM may have a chance to join that group. By 2020, IDC predicts, 60 percent of the A.I. applications will run on the platform of four companies: Amazon, Google, Microsoft and IBM.
UBS estimates that Watson may generate $500 million in revenue this year and could grow rapidly in the years ahead, possibly hitting nearly $6 billion by 2020 and almost $17 billion by 2022.
Having lived through The Great Cloud Forecasting era around the turn of the decade, my advice is: take all this with care, but enjoy the razzle-dazzle!